carcinoma (SCLC): the angiogenic phenomenon . Eur J Cardiothorac Surg 2002 ; 21 : 1105 – 1110 . 34. Sandler A Szwaric S Dowlati A . A phase II study of cisplatin plus etoposide plus bevacizumab for previously untreated extensive stage small
Search Results
Novel Systemic Therapies for Small Cell Lung Cancer
Charles M. Rudin, Christine L. Hann, Craig D. Peacock, and D. Neil Watkins
Systemic Therapy for Advanced Pancreatic Neuroendocrine Tumors: An Update
Diane L. Reidy-Lagunes
with a fluorouracil, oxaliplatin, and bevacizumab combination. The first by Bergsland et al. 37 reported a 50% response rate in 12 patients with progressive pancNETs who received short-term infusional 5-fluorouracil plus leucovorin (FOLFOX) and
Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes
Michael S. Lee, David G. Menter, and Scott Kopetz
Consensus Molecular Subtypes Primary CRC site is prognostic but not predictive of outcome with bevacizumab-based therapy. An analysis of 2 prospective randomized controlled trials of chemotherapy with or without bevacizumab found that a statistical
NCCN Evidence Blocks
Robert W. Carlson and Eric Jonasch
agents are available for the adjuvant treatment of resected primary RCC, multiple agents are available for metastatic disease, including the antiangiogenic agents sunitinib, pazopanib, bevacizumab/interferon, sorafenib, axitinib, and recently approved
Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer
Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortes, Scott Ramsey, Andrew Briggs, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, and Peter A. Fasching
focused on patients with TNBC, whereas the other RCTs included patients with any or broader BC subtypes (eg, HER2-negative) but reported TNBC-specific results. A variety of investigational neoadjuvant interventions were evaluated, including bevacizumab in
Routine Imaging or No Routine Imaging, Is That the Question?
Laurie Elit, Gregory R. Pond, and Mark N. Levine
group of only 4 providers. Further, during the 16-year period of this study, practice patterns would likely have changed substantially due to the introduction of PARP inhibitors or bevacizumab. The study included no data on whether patients receiving
NCCN Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
Featured Updates to the NCCN Guidelines
Al B. Benson III, Michael I. D’Angelica, Daniel E. Abbott, Thomas A. Abrams, Steven R. Alberts, Daniel A. Anaya, Robert Anders, Chandrakanth Are, Daniel Brown, Daniel T. Chang, Jordan Cloyd, Anne M. Covey, William Hawkins, Renuka Iyer, Rojymon Jacob, Andreas Karachristos, R. Kate Kelley, Robin Kim, Manisha Palta, James O. Park, Vaibhav Sahai, Tracey Schefter, Jason K. Sicklick, Gagandeep Singh, Davendra Sohal, Stacey Stein, G. Gary Tian, Jean-Nicolas Vauthey, Alan P. Venook, Lydia J. Hammond, and Susan D. Darlow
(doxorubicin) led to less consensus among the panel. Bevacizumab, another VEGF receptor inhibitor, has modest clinical activity (as a single agent or in combination with other systemic therapy options) in phase II studies in patients with advanced HCC. 39 – 43
Accelerated Approval Program Versus NCCN Guidelines as Mechanisms for Early Drug Access
Austin Wesevich and Mark J. Ratain
5 years after the AA date, although more recent withdrawals have been within 3 years of AA. One concern is that prior AA indications persist in NCCN Guidelines despite unsuccessful confirmatory trials. 12 For example, bevacizumab received AA on
Non–Small Cell Lung Cancer
David S. Ettinger, Wallace Akerley, Gerold Bepler, Matthew G. Blum, Andrew Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Todd L. Demmy, Apar Kishor P. Ganti, Ramaswamy Govindan, Frederic W. Grannis Jr., Thierry Jahan, Mohammad Jahanzeb, David H. Johnson, Anne Kessinger, Ritsuko Komaki, Feng-Ming Kong, Mark G. Kris, Lee M. Krug, Quynh-Thu Le, Inga T. Lennes, Renato Martins, Janis O'Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, George R. Simon, Scott J. Swanson, Douglas E. Wood, and Stephen C. Yang
whom the standard premedications (i.e., dexamethasone, H2 blockers, H1 blockers) are contraindicated. 212 , 213 Specific targeted therapies have been developed for treating advanced lung cancer. 214 , 215 Bevacizumab is a recombinant monoclonal
Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer?
Virginia G. Kaklamani and William J. Gradishar
phase II clinical trial evaluating the role of bevacizumab and carboplatin in TNBC. The trial had a 2 x 2 factorial design. Patients received preoperative chemotherapy with paclitaxel, 80 mg/m 2 weekly for 12 weeks followed by AC for 4 cycles. Patients